Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- Chester Oddis
- Study ID
- NCT02043548
- Phase
- PHASE2
- Status
- Completed
Conditions
- Dermatomyositis
- Polymyositis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- tocilizumab — DRUGgiven at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
- placebo — DRUGgiven by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
Study Details
The purpose of this multi-center pilot study is to determine if the drug tocilizumab (Actemra) is effective in the treatment of patients with refractory adult polymyositis (PM) and dermatomyositis (DM).
Key Dates
- Start date
- Oct 1, 2014
- Status verified
- Oct 2020
- Primary completion
- Jul 30, 2019
- Completion
- Jul 31, 2019
Study Design
- Enrollment
- 36 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Group A: TocilizumabTocilizumab will be given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
- Placebo Comparator: Group B: PlaceboPlacebo arm - no active drug
Primary Outcome Measure
Compare the Average Total Improvement Scores at Visits 2 Through 7 During the 6-month Treatment Period Between the Treatment and Placebo Arms [ Time Frame: Week 4, 8, 12, 16, 20, and 24 ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | - |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | - |
| Mayo Clinic | Rochester | Minnesota | 55905 | - |
| North Shore Long Island Jewish Center | Great Neck | New York | 11021 | - |
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15261 | - |
| Vanderbilt University | Nashville | Tennessee | 37235 | - |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Los Angeles, CA
Related Studies
- Environmental Risk Factors for the Anti-synthetase SyndromeRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Miami, Florida
- Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyPHASE3 · Enrolling By Invitation · argenx · Phoenix, Arizona